covid-19 subunit vaccine candidate, developed by US-based Baylor College of Medicine, in India following approval from the Drugs Controller General of India (DGCI).
The vaccine candidate is fourth to start human trials in India.The Hyderabad-based vaccine manufacturer has partnered with Baylor College and US-based Dynavax Technologies Corporation for development of the vaccine.“We are very happy indeed to transition our potential vaccine candidate to clinical trials and offer one more potential option for the prophylaxis of COVID-19," Biological E managing director Mahima Datla said in a statement.Biological E expects the results of the phase I and II clinical trials to be available by February.Biological E’s vaccine candidate includes an.